The study looks at an oral non-peptide GLP-1 drug in Japanese adults, a group researchers say is more prone to metabolic disease.
Recap by typeshit. Full story at The Lancet.
2:21
The Las Vegas station covers Lilly's experimental retatrutide and why researchers see it as a potential step up in weight loss.
Function Health points out that the body produces GLP-1 itself and lists ways it says can boost it. The claims are the company's own.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
32:59
Tatem discusses tesamorelin and his view that it can reshape the body without moving the scale. Treat the claims as his own, not settled fact.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
Ali Ghulam and colleagues report in Genomics & Informatics that a capsule neural network beat CNN and LSTM baselines using dipeptide composition features.
Loading…